Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk

Endocrine-Related Cancer

Volumn 15, Issue 4, 2008, Pages 1055-1060

  Goodman, Marc T ^a   Lurie, Galina ^a   Thompson, Pamela J ^a   McDuffie, Katharine E ^a   Carney, Michael E ^b  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; AROMATASE; ESTROGEN; GUANINE;

ADULT; AGE DISTRIBUTION; AGED; ALLELE; ARTICLE; CANCER RISK; CAUCASIAN; CODOMINANCE; CONTROLLED STUDY; ESTROGEN SYNTHESIS; ETHNICITY; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; OVARY CANCER; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AROMATASE; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HAWAII; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 58249117814     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-08-0104     Document Type: Article

References (29)

1. Arvanitis DA, Koumantakis GE, Goumenou AG, Matalliotakis IM, Koumantakis EE & Spandidos DA 2003 CYP1A1, CYP19, and GSTM1 polymorphisms increase the risk of endometriosis. Fertility and Sterility 79 (Suppl 1) 702-709.
2. Barrett JC, Fry B, Maller J & Daly MJ 2005 Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 263-265.
3. Beral V, Million Women Study Collaborators, Bull D, Green J & Reeves G 2007 Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369 1703-1710.
4. Bulun SE, Chen D, Lu M, Zhao H, Cheng Y, Demura M, Yilmaz B, Martin R, Utsunomiya H, Thung S et al. 2007 Aromatase excess in cancers of breast, endometrium and ovary. Journal of Steroid Biochemistry and Molecular Biology 106 81-96.
5. Cai Q, Kataoka N, Li C, Wen W, Smith JR, Gao YT, Shu XO & Zheng W 2008 Haplotype analyses of CYP19A1 gene variants and breast cancer risk: results from the Shanghai Breast Cancer Study. Cancer Epidemiology, Biomarkers and Prevention 17 27-32.
6. Cramer DW & Welch WR 1983 Determinants of ovarian cancer risk. II. Inference regarding pathogenesis. Journal of the National Cancer Institute 71 717-721.
7. Folsom AR, Anderson JP & Ross JA 2004 Estrogen replacement therapy and ovarian cancer. Epidemiology 15 100-104.
8. Goodman MT, McDuffie K, Kolonel LN, Terada K, Donlon TA, Wilkens LR, Guo C & Le Marchand L 2001 Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiology, Biomarkers and Prevention 10 209-216.
9. Haiman CA, Stram DO, Pike MC, Kolonel LN, Burtt NP, Altshuler D, Hirschhorn J & Henderson BE 2003 A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort. Human Molecular Genetics 12 2679-2692.
10. Haiman CA, Dossus L, Setiawan VW, Stram DO, Dunning AM, Thomas G, Thun MJ, Albanes D, Altshuler D, Ardanaz E et al. 2007 Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Research 67 1893-1897.
11. Kado N, Kitawaki J, Obayashi H, Ishihara H, Koshiba H, Kusuki I, Tsukamoto K, Hasegawa G, Nakamura N, Yoshikawa T et al. 2002 Association of the CYP17 gene and CYP19 gene polymorphisms with risk of endometriosis in Japanese women. Human Reproduction 17 897-902.
12. Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A & Schairer C 2002 Menopausal hormone replacement therapy and risk of ovarian cancer. Journal of the American Medical Association 288 334-341.
13. Lacey JV Jr, Brinton LA, Leitzmann MF, Mouw T, Hollenbeck A, Schatzkin A & Hartge P 2006 Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health - AARP Diet and Health Study Cohort. Journal of the National Cancer Institute 98 1397-1405.
14. Li YF, Hu W, Fu SQ, Li JD, Liu JH & Kavanagh JJ 2008 Aromatase inhibitors in ovarian cancer: is there a role? International Journal of Gynecological Cancer 18 600-614.
15. Lukanova A & Kaaks R 2005 Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiology, Biomarkers and Prevention 14 98-107.
16. Lurie G, Thompson P, McDuffie KE, Carney ME, Terada KY & Goodman MT 2007 Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk. Obstetrics and Gynecology 109 597-607.
17. Narod SA 2007 Ovarian cancer and HRT in the Million Women Study. Lancet 369 1667-1668.
18. Ness RB 2003 Endometriosis and ovarian cancer: thoughts on shared pathophysiology. American Journal of Obstetrics and Gynecology 189 280-294.
19. Paynter RA, Hankinson SE, Colditz GA, Kraft P, Hunter DJ & De Vivo I 2005 CYP19 (aromatase) haplotypes and endometrial cancer risk. International Journal of Cancer 116 267-274.
20. Pike MC, Pearce CL, Peters R, Cozen W, Wan P & Wu AH 2004 Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertility and Sterility 82 186-195.
21. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Weiderpass E & Persson IR 2002 Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. Journal of the National Cancer Institute 94 497-504.
22. Risch HA 1998 Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. Journal of the National Cancer Institute 90 1774-1786.
23. Rodriguez C, Patel AV, Calle EE, Jacob EJ & Thun MJ 2001 Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. Journal of the American Medical Association 285 1460-1465.
24. Sit AS, Modugno F, Weissfeld JL, Berga SL & Ness RB 2002 Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. Gynecologic Oncology 86 118-123.
25. Stephens M, Smith NJ & Donnelly P 2001 A new statistical method for haplotype reconstruction from population data. American Journal of Human Genetics 68 978-989.
26. Stocco C 2008 Aromatase expression in the ovary: hormonal and molecular regulation. Steroids 73 473-487.
27. Tao MH, Cai Q, Zhang ZF, Xu WH, Kataoka N, Wen W, Xiang YB, Zheng W & Shu XO 2007 Polymorphisms in the CYP19A1 (aromatase) gene and endometrial cancer risk in Chinese women. Cancer Epidemiology, Biomarkers and Prevention 16 943-949.
28. Yager JD & Liehr JG 1996 Molecular mechanisms of estrogen carcinogenesis. Annual Review of Pharmacology and Toxicology 36 203-232.
29. Zheng H, Kavanagh JJ, Hu W, Liao Q & Fu S 2007 Hormonal therapy in ovarian cancer. International Journal of Gynecological Cancer 17 325-338.